Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Blood
Lydia RoyFrançois Guilhot

Abstract

In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P < .001, P = .004, and P < .001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, wit...Continue Reading

References

Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Jul 31, 1999·Annals of Internal Medicine·S FaderlH M Kantarjian
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Nov 8, 2001·Blood·F BonifaziUNKNOWN Swedish CML Study Group
Feb 28, 2002·Blood·Michele BaccaraniUNKNOWN Italian Cooperative Study Group on Myeloid Leukemia
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A HahnUNKNOWN IRIS Investigators
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hagop KantarjianMoshe Talpaz
Aug 21, 2004·Blood·Michele BaccaraniUNKNOWN GIMEMA Working Party on Chronic Myeloid Leukemia

❮ Previous
Next ❯

Citations

Jul 31, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ingo Roeder, Ingmar Glauche
Apr 29, 2010·Current Hematologic Malignancy Reports·Meetu AgrawalAlfonso Quintás-Cardama
Apr 29, 2010·Current Hematologic Malignancy Reports·Maxim Norkin, Charles A Schiffer
Mar 14, 2012·Current Hematologic Malignancy Reports·Delphine ReaFrançois-Xavier Mahon
Dec 6, 2011·Bone Marrow Transplantation·K PerruccioA Velardi
Apr 4, 2008·Nature Reviews. Cancer·Michael Savona, Moshe Talpaz
May 15, 2007·Leukemia·T MughalJ M Goldman
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Jul 10, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BaccaraniUNKNOWN ESMO Guidelines Working Group
May 2, 2007·Journal of the National Cancer Institute·Margret S Rodrigues, Martin Sattler
Nov 29, 2007·Current Opinion in Oncology·Dragana Milojkovic, Jane Apperley
Jan 22, 2011·Current Opinion in Hematology·Ross A Okimoto, Richard A Van Etten
Dec 17, 2009·Hematology·John M Goldman
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesHagop Kantarjian
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesHagop Kantarjian
Nov 19, 2009·Drug Design, Development and Therapy·Carmen FavaElias Jabbour
Aug 18, 2009·Journal of Neurosurgery·Austin K MattoxD Cory Adamson
Dec 27, 2013·Journal of Clinical and Experimental Hematopathology : JCEH·Hiroko TsunemineTakayuki Takahashi
Nov 28, 2012·Cancer Immunology, Immunotherapy : CII·Stefanie Andrea Erika HeldAnnkristin Heine
Jan 27, 2007·Current Opinion in Hematology·Ehab Atallah, Jorge Cortes
Apr 10, 2008·Leukemia & Lymphoma·François GuilhotAli Turhan
Dec 11, 2007·Leukemia & Lymphoma·Lisa Kujawski, Moshe Talpaz
Nov 16, 2006·Expert Opinion on Therapeutic Targets·Nicholas W Choong, Ezra E W Cohen
Oct 13, 2015·International Journal of Cancer. Journal International Du Cancer·Belal FirwanaAref Al-Kali
Mar 21, 2012·Expert Opinion on Pharmacotherapy·Maria Florencia TanakaElias Jabbour
Oct 1, 2008·Expert Review of Hematology·Dominik Heim, Alois Gratwohl
Feb 1, 2009·Expert Review of Hematology·Stefan Schmidt, Dominik Wolf
Aug 24, 2007·Expert Opinion on Investigational Drugs·Pellegrino Musto, Fiorella D'Auria

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.